Business Context and Reporting Period
Company: Glucotrack, Inc. (GCTK)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Glucotrack is a holding company with two primary subsidiaries: Lokahi Therapeutics (developing LT-100, a bee venom-based therapy for osteoarthritis) and Glucotrack Technologies (developing an implantable continuous blood glucose monitor, CBGM). The company is a clinical-stage biopharmaceutical and medical device entity with no commercial revenue to date.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(8,148) | $(11,589) | $(3,814) | $(4,756) |
| Operating Expenses | $7,603 | $8,294 | $3,400 | $4,796 |
| Cash and Cash Equivalents (End of Period) | $1,124 | $9,555 | $1,124 | $9,555 |
| Net Cash Used in Operating Activities | $(7,664) | $(6,683) | N/A | N/A |
| Total Debt (Promissory Notes + Loans) | $1,940 | N/A | N/A | N/A |
| Stockholders' Equity (Deficit) | $(1,741) | $6,880 | $(1,741) | $6,880 |
Note: The filing does not provide a clear value for "Total Debt" for the prior year comparable period in the summary tables, though specific note balances are listed in the balance sheet.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately 30% for the six-month period (from $11.6M to $8.1M) and by 20% for the three-month period (from $4.8M to $3.8M), primarily due to lower R&D and G&A expenses.
- Expense Reduction: Research and Development expenses declined from $5.0M to $4.1M (six months) due to reduced product and manufacturing costs. General and Administrative expenses increased slightly for the six-month period ($3.3M to $3.5M) but decreased for the three-month period ($1.6M to $1.4M).
- Derivative Liability Volatility: The change in fair value of derivative liabilities shifted from a significant gain of $3.3M in the prior year to a negligible loss of $1K in the current period.
- Cash Burn: Cash and cash equivalents dropped significantly from $7.4M at year-end 2025 to $1.1M at June 30, 2026, driven by operating cash outflows of $7.7M.
- Equity Structure: The company executed two reverse stock splits in 2025 (1-for-20 and 1-for-60) and issued significant shares for debt conversion and ELOC financing, increasing outstanding shares from ~910k to ~6.3M.
Guidance, Outlook, Risks, and Unusual Items
Subsequent Events and Financing
- Business Combination: On July 14, 2026, Glucotrack entered into a Merger Agreement with Lokahi Therapeutics. Lokahi will become a wholly-owned subsidiary. Existing Glucotrack shareholders are guaranteed a minimum 10% ownership floor post-transaction.
- Bridge Financing: The company secured approximately $4.45M in gross proceeds via senior secured convertible promissory notes (Bridge Notes) and a follow-on investment of $3.5M in August 2026.
- PIPE Financing: An Interim PIPE transaction closed in August 2026 raising $2.0M via pre-funded warrants.
- ELOC: A new Equity Line of Credit (ELOC) for up to $50M was established with White Lion Capital, LLC.
Risks and Going Concern
- Substantial Doubt: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months due to recurring losses, an accumulated deficit of $160M, and limited cash ($1.1M).
- Nasdaq Delisting: The company received a Staff Determination from Nasdaq to delist its securities due to failure to meet the $1.00 minimum bid price and the $2.5M minimum stockholders' equity requirements. The company is appealing and plans to regain compliance via the Business Combination.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including IT controls and segregation of duties.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1M cash balance against the $7.7M operating burn rate and the timing of proceeds from the Bridge Financing and PIPE.
- Nasdaq Status: Confirm the outcome of the Nasdaq delisting appeal and the timeline for the Business Combination to restore listing compliance.
- Debt Terms: Review the specific terms of the Bridge Notes (8% interest, 22% OID, 9-month maturity) and the security interest granted on company assets.
- Merger Dilution: Analyze the final capitalization table post-merger to understand the dilution impact on existing shareholders versus the new Lokahi shareholders and PIPE investors.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting and IT systems.